Eiropas Savienība - latviešu - EMA (European Medicines Agency)

vbi vaccines b.v. - hepatīta b virsmas antigēns - b hepatīts - vakcīnas - prehevbri is indicated for active immunisation against infection caused by all known subtypes of the hepatitis b virus in adults. it can be expected that hepatitis d will also be prevented by immunisation with prehevbri as hepatitis d (caused by the delta agent) does not occur in the absence of hepatitis b infection. the use of prehevbri should be in accordance with official recommendations.

Latvija - latviešu - Pārtikas un veterinārais dienests, Zemkopības ministrija

kapsula

Latvija - latviešu - Pārtikas un veterinārais dienests, Zemkopības ministrija

kapsula

Latvija - latviešu - Pārtikas un veterinārais dienests, Zemkopības ministrija

kapsula

Latvija - latviešu - Pārtikas un veterinārais dienests, Zemkopības ministrija

kapsula

Latvija - latviešu - Pārtikas un veterinārais dienests, Zemkopības ministrija

kapsula

Latvija - latviešu - Pārtikas un veterinārais dienests, Zemkopības ministrija

kapsula

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

accord healthcare s.l.u. - abiraterona acetāts - prostatas audzēji - endokrīnā terapija - abiraterone accord is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicatedthe treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

mylan ireland limited - abiraterona acetāts - prostatas audzēji - endocrine therapy, other hormone antagonists and related agents - abiraterone mylan is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt). the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.